

26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD



Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Kevin L. Winthrop, MD, MPH
Professor, Divisions of Infectious Diseases,
Public Health and Preventive Medicine
Oregon Health & Science University

7/1/2024



Disclosures of Financial Relationships with Relevant Commercial Interests

- Research Grant---Insmed
- Consultant---Insmed, Spero, Paratek, AN2

Nontuberculous Mycobacterium (NTM)

- "MOTT" or "Atypical"
- Environmental organisms
 - Soil, lakes, rivers, municipal water systems
 - Resistant to chlorine and most disinfectants
- Biofilm
 - Live within amoeba, legionella, others

Laboratory Growth Characteristics

- "Slow" growers (>2 weeks in AFB media, liquid media more quickly)
 - *M. avium* complex (MAC), *M. kansasii*, *M. marinum*, *M. xenopi*
- "Rapid" growers (4-7 days in routine blood agar)
 - *M. abscessus*, *M. chelonae*, *M. fortuitum*
- "Need help" growing
 - *M. goodii*, *M. haemophilum*, *M. ulcerans*
 - *M. genavense* (often molecular ID)

NTM Disease Clinical Manifestations

- Pulmonary (75%)
 - MAC
 - *M. kansasii*
 - *M. xenopi*
 - *M. abscessus*
 - *M. malmoense*

NTM Disease Clinical Manifestations

<ul style="list-style-type: none">• Skin and Soft tissue (15%)<ul style="list-style-type: none">• MAC, <i>M. marinum</i>, <i>M. abscessus</i>, <i>M. chelonae</i>, <i>M. fortuitum</i>, <i>M. kansasii</i>, <i>M. ulcerans</i>• Lymph node disease (5%)<ul style="list-style-type: none">• MAC, (historically also <i>M. scrofulaceum</i>)	<ul style="list-style-type: none">• Disseminated (5%)<ul style="list-style-type: none">• MAC, <i>M. kansasii</i>, <i>M. abscessus</i>, <i>M. chelonae</i>, <i>M. haemophilum</i>• Hypersensitivity pneumonitis (0%)<ul style="list-style-type: none">• MAC and hot tubs
---	--

26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD

Important Bug-Setting Associations

- Corneal Disease
 - *M. chelonae*
- Healthcare/hygiene associated outbreaks
 - *M. abscessus*, *M. fortuitum*, *M. abscessus*, *M. chimaera*
- Line-associated
 - *M. mucogenicum*
- HIV setting
 - MAC, *M. kansasii*, *M. genavense*, *M. haemophilum*
- Tropical setting
 - *M. ulcerans* (buruli ulcer)

Other Pearls Based on Species

- *M. goodii*
- *Corynebacterium*
- NTM are not communicable
 - CF?
- *M. immunogenium*, *M. simiae*
 - Pseudo-outbreaks
- *M. szulgai*, *M. kansasii*, and *M. marinum*
 - Cross-react with IGRAs
- *M. fortuitum* lung disease
 - Aspiration
- *M. marinum*
 - Fish and fish tanks

Question #1

PREVIEW QUESTION

72 year old female with chronic cough, normal CXR, and 1/3 sputums grow MAC. Which one of the following do you recommend?

- A. CT scan of chest AND Additional sputum AFB cultures
- B. Empiric therapy with azithromycin, ethambutol, and rifampin
- C. Additional sputum AFB cultures
- D. Wait for in vitro susceptibility data and then treat.

Question #1

PREVIEW QUESTION

72 year old female with chronic cough, normal CXR, and 1/3 sputums grow MAC. Which one of the following do you recommend?

- A. **CT scan of chest AND Additional sputum AFB cultures ***
- B. Empiric therapy with azithromycin, ethambutol, and rifampin
- C. Additional sputum AFB cultures
- D. Wait for in vitro susceptibility data and then treat.

Pulmonary NTM

IGRA/AFB/IDS/No diagnostic criteria

- Patient has both radiographic evidence of disease and pulmonary symptoms
- AND
- At least 2 sputum cultures positive, or
- One BAL or tissue specimen with positive culture, or
- Tissue with granulomatous histopathology in conjunction with positive culture (BAL or sputum)

Griffith D et al. AJRCCM 2007

Pulmonary NTM

- MAC is most common etiology (60-98%)
- *M. kansasii* and *M. abscessus*
 - *M. kansasii* primarily in the South
 - Recent *M. abscessus* increase in CF
- Other organisms of importance
 - *M. xenopi* (northern US/ Canada, Europe)
 - *M. malmoense* (Europe)




26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD

Two Types of MAC Pulmonary Diseases

- **Macrocystic Smoker's COPD**
 - Apical cavity or fibronodular disease
 - More rapidly progressive
- **Macrocystic Smoker's (Windermere®)**
 - Scoliosis, thin, pectus deformities, hypomastia
 - Nodular and interstitial nodular infiltrate
 - Bronchiectasis right middle lobe / lingula
 - Bronchiolitis ("tree and bud") on HRCT
 - Slowly progressive

*Iseman MD et al. Am Rev Respir Dis. 1991



Pulmonary NTM Risk Factors

- Underlying lung architectural abnormalities
 - Bronchiectasis, CF, α-1, emphysema
 - Prior TB, GERD/aspiration
- Exposure/transmission
 - Gardening/soil, Hot tubs
- Immunosuppressives
 - Prednisone, inhaled corticosteroids, biologics

NTM Pulmonary Disease Diagnosis

- **Diagnosable** = decision to treat
- **Observation vs. suppression vs. cure**

26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD

MAC Therapeutic Options

- Treatment best defined for MAC
- Start with rifampin and ethambutol
- Amikacin first 1-2 months for cavitory disease
- Treatment duration 18-24 months (12 month culture negative)
- Macrolide monotherapy is contraindicated
- Recommended to test susceptibility for macrolide
 - If susceptible, if non-cavitary or not re-infection

Pulmonary *M. kansasii* Therapy

- *M. kansasii* clinically more like TB
- Thin-walled cavities, upper lobes
- Treatment with INH, RIF, EMB
- T1W therapy ok
- Treatment duration: 12 months culture negativity
- High treatment success rates (90%+)
- RIF is key drug
 - EQ or Macrolide useful in RIF-resistant disease

Pulmonary *M. abscessus* ssp. Therapy

- Includes *M. massiliense*, *M. abscessus*
- High level of clindamycin resistance – erm (41) gene
- "Cure" – rare
- Can be more rapidly progressive than MAC
- 3-4 drugs for 18-24 months
 - 4-6 months "induction" phase
 - "suppressive strategy" thereafter

M. abscessus Therapy

- Parenteral agents
 - Omadacycline 100mg QD, Tigecycline 50mg QD, Ceftazidime 2gm TID, Imipenem 1000mg BID, Amikacin 10mg/kg T1W
- Oral agents
 - Clotazimine 50/100mg QD, Linezolid 600mg QD, moxifloxacin 400mg QD (rarely suscep), Azithromycin 250mg QD (if suscep), Omadacycline 300mg QD
- Surgical resection

Extrapulmonary NTM

- 1. Immunocompetent settings
- 2. Immunocompromised settings

Immunocompetent settings

- Nail salon, trauma, surgical or injection procedures, fish tank, hot tubs
- Rapid or slow growing NTM
- Incubation period
 - Infection usually occurs 2-8 weeks after contact with contaminated water source

26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts


Speaker: Kevin Winthrop, MD

Children under 5 years NTM > TB



- Usually MAC
 - Males > females, age 1-2 years old
- Surgical resection alone is best therapy
- Adjunctive ABX rarely needed

Post- plastic surgery



- Usually Rapid Grower: *M. chelonae*
- Remove foreign-bodies
- Therapy as per in-vitro susceptibility
- Length 4-6 months

M. marinum --- fish tank granuloma



Treatment: multiple drugs


- Macrolides, sulfonamides, doxycycline, rifampin, ethambutol
- Treat with 2 agents X 3-4 months
- Surgical debridement if necessary

Nail Salon Furunculosis



- Outbreaks and sporadic
- Rapid Growers most common (*M. fortuitum*)
- Oral antibiotics
 - 4 months fluoroquinolone and/or doxycycline
 - Can be self-limited

Tattoo-associated



- *M. chelonae*
- Tattoo-ink outbreaks
- 2-3 months oral therapy
 - Based on in-vitro susceptibility
 - 1-2 agents
 - Macrolides almost always

Question # 2

PREVIEW QUESTION

20 y.o. male complains of fever, night sweats and weight loss. Has generalized lymphadenopathy.

HIV antibody positive, CD4 20 cells/ul

Node biopsy: non-caseating granuloma, AFB seen.

26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD

Question # 2  **PREVIEW QUESTION**

Based on the most likely diagnosis, which of the following do you recommend?

- A. Start MAC therapy
- B. Start HAART plus MAC prophylaxis
- C. Start MAC therapy and HAART
- D. Start HAART only

Question # 2  **PREVIEW QUESTION**

Based on the most likely diagnosis, which of the following do you recommend?

- A. Start MAC therapy
- B. Start HAART plus MAC prophylaxis
- C. **Start MAC therapy and HAART ***
- D. Start HAART only

NTM in HIV

- Disseminated MAC
- GI route of infection
- Less frequent in HAART era
- Related Issues
 - Clofazimine = increases mortality
 - Rifabutin dose adjustment with PI
 - Immune reconstitution inflammatory syndrome (IRIS)

Preferred (A, B)*	Alternative (B, E)*
Treatment	
Clarithromycin 500 mg orally twice daily	Azithromycin 500 mg daily
Ethambutol 15 mg/kg orally daily	Ethambutol 15 mg/kg daily
Rifabutin† 300 mg orally daily	Rifabutin† 300-450 mg orally daily
	Clarithromycin 500 mg orally twice daily or Rifabutin† 300 mg orally daily
Prevention‡	
Azithromycin 1,200 mg orally weekly	Clarithromycin 500 mg orally twice daily or Rifabutin† 300 mg orally daily

* For evidence quality, see Table 1.
 † Rifabutin dose may need to be modified based on drug-drug interactions (see text).
 ‡ Prophylactic therapy indicated for persons with < 50 CD4+ cells/μL; may stop if > 100 cells/μL.

Griffith D et al. AJRCCM 2007

Immunosuppression other than HIV

- Most frequently disseminated
 - Local (nasal) or Varicella (3-10%)
- Risk factors and conditions
 - ESRD, prednisone, biologic immunosuppressives
 - Cancer, transplant, leukemia (hairy cell)
 - Auto-antibody and cytokine/receptor deficiency states
 - TNF-inhibitors, IL-2/23 pathway, STAT-1
- Disease split between RGM and slow growers
 - RGM more common here than in pulmonary disease

M. chelonae in cancer patient



M. chelonae and M. fortuitum treatment

- **M. chelonae**
 - Macrolides, fluoroquinolone, linezolid
 - IV drugs include aminoglycosides, imipenem, ceftazidime, tigecycline
- **M. fortuitum**
 - Macrolides, fluoroquinolone, bacitracin, doxy (50%)
 - IV drugs include aminoglycosides, imipenem, ceftazidime, tigecycline


Length of treatment for disseminated infection
 3 drugs (including 1 IV) X 4-6 months
 Depends on immunosuppression reversal

26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD


M. chimaera

- Slow growing *M. avium* complex
- Pulmonary disease
- Extrapulmonary disease
 - 150+ cases from open heart surgery: prosthetic valve, vascular graft, TAVI, heart transplant
- Aerosol from contaminated heater-cooler units used in operating room for cardiac by-pass
- Time to diagnosis: 7-3.6 years post-op, with cases reported up to 6 years postoperatively
- Mycobacterial blood cultures
- Treatment: forever?



Hansen's Disease (Leprosy)

- Rare in US (100-200 cases per year)
- Americas and Gulf region
- Rest imported
- Most humans resistant
- Household contacts at risk (low risk)
- Nasopharyngeal transmission?
- *M. leprae* does not grow in culture



Leprosy Disease Classification

<u>Paucibacillary (PB)</u>	<u>Multibacillary (MB)</u>
<ul style="list-style-type: none">• Most common form• Tuberculoid• Bacillary load < 1 million• Skin biopsy: AFB negative• < 5 skin lesions	<ul style="list-style-type: none">• Lemmatous• Massive bacillary load• Skin biopsy: floridly positive for AFB• > 5 skin lesions



26 – Nontuberculous Mycobacteria in Normal and Abnormal Hosts

Speaker: Kevin Winthrop, MD




Leprosy Treatment

- PB (6-12 months)
 - Dapsone 100mg daily
 - Clofazimine 50mg daily
 - Rifampin 600mg once monthly
- MB (12-24 months)
 - Dapsone 100mg daily
 - Clofazimine 30mg daily
 - Rifampin 600mg daily

(US guidelines are daily RIF and no Clofaz for 12 months)

(resist: *M. leprae*, *M. mageritensis*, *M. goodii*, *M. neoaurum*, *M. indicus pranii*, *M. neoaurum*, *M. indicus pranii*, *M. neoaurum*, *M. indicus pranii*, *M. neoaurum*, *M. indicus pranii*, *M. neoaurum*, *M. indicus pranii*)



Top 10 or 12 NTM pearls for the Boards

- Footbaths = *M. fortuitum* or other RGM
- Plastic Surgery = *M. chelonae* or other RGM
- Equatorial Africa = *M. ulcerans*
- HIV disseminated MAC that doesn't grow = think of *M. genavense*
- *M. abscessus* usually has inducible macrolide resistance (erm gene)
- Macrolide, EMB, RIF for 18-24 months for pulmonary MAC
- *M. goodii* is 99.9% a contaminant
- ATS/IDSA pulmonary case definition: need one BAL or two sputums or tissue
- Know NTM species that cross-react with TB IGRA's
- No clofazimine in HIV related MAC
- *M. kansasii* behaves like TB—responds to TB drugs (NIF, EMB, INH)
- PZA not useful for any NTM